Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Royalty Pharma Plc Cl A 110 East 59th Street New York NY 10022 USA

www.royaltypharma.com P: 212-883-0200

Description:

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.

Key Statistics

Overview:

Market Capitalization, $K 16,495,181
Enterprise Value, $K 22,153,462
Shares Outstanding, K 597,435
Annual Sales, $ 2,355 M
Annual Net Income, $ 1,135 M
Last Quarter Sales, $ 596,070 K
Last Quarter Net Income, $ 494,340 K
EBIT, $ 1,492 M
EBITDA, $ 1,513 M
60-Month Beta 0.45
% of Insider Shareholders 18.72%
% of Institutional Shareholders 54.35%
Float, K 485,595
% Float 81.28%
Short Volume Ratio 0.48

Growth:

1-Year Return -22.29%
3-Year Return -36.05%
5-Year Return 0.00%
5-Year Revenue Growth 31.18%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.15 on 02/15/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm 4.39
EPS Growth vs. Prev Qtr 45.57%
EPS Growth vs. Prev Year -26.28%
Annual Dividend Rate, $ 0.81
Annual Dividend Yield 2.93%
Most Recent Dividend 0.210 on 02/15/24
Next Ex-Dividends Date 05/16/24
Dividend Payable Date 06/14/24
Dividend Payout Ratio 18.19%

RPRX Ratios

Ratio
Price/Earnings ttm 6.26
Price/Earnings forward 7.15
Price/Earnings to Growth 0.80
Return-on-Equity % 26.93%
Return-on-Assets % 15.93%
Profit Margin % 48.20%
Debt/Equity 0.61
Price/Sales 6.97
Price/Cash Flow 6.19
Price/Book 1.67
Book Value/Share 16.88
Interest Coverage 10.08

RPRX Dividends

Date Value
02/15/24 $0.2100
11/16/23 $0.2000
08/17/23 $0.2000
05/18/23 $0.2000
02/15/23 $0.2000
11/17/22 $0.1900
08/18/22 $0.1900
05/19/22 $0.1900
02/17/22 $0.1900
11/18/21 $0.1700
08/19/21 $0.1700
05/19/21 $0.1700
02/18/21 $0.1700
11/19/20 $0.1500
09/14/20 $0.1500
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar